All News

Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.

Vorasidenib monotherapy appears to improve clinical outcomes among patients with IDH-mutant low-grade glioma, meeting 2 end points in the phase 3 INDIGO trial.

Factors including age, gender, and facility type may influence the likelihood of pain specialist referrals for lung cancer, suggesting a need for multidisciplinary pain management in this patient population.

EP0042 shows promising early clinical efficacy in patients with pretreated acute myeloid leukemia, according to investigators.

Anthony D’Amico, MD, PhD, reviewed current practices and unanswered questions surrounding radiotherapy in the realm of prostate cancer.

Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.

Matthew Dallos, MD, discusses current challenges in the treatment of castration-resistant prostate cancer and the potential of antibody-drug conjugates in this disease space.

The addition of bortezomib to dexamethasone plus rituximab and cyclophosphamide appears to improve progression-free survival among those with Waldenström Macroglobulinemia.

Investigators indicate that strategies are necessary to identify patients with extensive-stage small cell lung cancer who won’t benefit from immunotherapy-based treatment.

Shilpa Gupta, MD, discusses bladder preserving strategies for unfit or young patients, trials assessing immunotherapy combinations, and results from the BLASST-1 trial presented at ASCO GU.

Nirogacestat may be a noteworthy therapeutic advance for patients with desmoid tumors, according to an expert from Memorial Sloan Kettering Cancer Center.

The final analysis of the phase 2/3 CCTG IND.227/KEYNOTE-483 trial identifies a statistically significant survival benefit with pembrolizumab and chemotherapy vs chemotherapy alone in the first-line setting for patients with unresectable advanced or metastatic malignant pleural mesothelioma.

Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.

Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.

Disparities in pediatric cancer survival in Europe might be mitigated through cross-border care, twinning programs, and use of pan-Europe cancer control plans.

The presence of teratoma in pretreatment non-seminomatous germ-cell tumors correlates with a higher risk of teratomatous elements in residual non- retroperitoneal disease following chemotherapy.

An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.

All patients with platinum-resistant, small-cell neuroendocrine prostate cancer who responded to treatment with BXCL701 plus pembrolizumab were microsatellite stable and/or tumor mutational burden–low with a low probability of response to pembrolizumab.

Polatuzumab vedotin-piiq plus R-CHP was found to produce clinical efficacy in phase 3 POLARIX trial in patients with previously untreated diffuse large B-cell lymphoma, leading to an 11-to-2 vote from the FDA’s Oncologic Drug Advisory Committee.

The phase 3 TORCHLIGHT study, examining toripalimab and paclitaxel, has become the first study in China to achieve positive outcomes with immunotherapy for triple-negative breast cancer.

Data from a phase 2 placebo-controlled trial may support darolutamide switch maintenance therapy following at least 1 androgen receptor pathway inhibitor and taxane chemotherapy in patients with metastatic castration-resistant prostate cancer.

Final analyses for pathologic response appear consistent with previous reports from the phase 3 AEGEAN trial evaluating neoadjuvant durvalumab and chemotherapy plus adjuvant durvalumab monotherapy in resectable non–small cell lung cancer.

Data from a prospective pilot study indicate that circulating tumor DNA may be a valuable prognostic biomarker in early-stage follicular lymphoma.

The FDA initially issued a complete response letter for remestemcel-L in pediatric steroid-refractory acute graft-versus-host disease in October 2020, citing a need for an additional randomized, controlled trial to confirm the agent’s efficacy.

Findings from a multicenter analysis indicate that tumor lysis syndrome is a notable risk in patients with mantle cell lymphoma receiving treatment with venetoclax.

Abatacept plus ruxolitinib and screenings for concomitant respiratory muscle failure may be effective in reducing the rate of mortality related to immune checkpoint inhibitor–associated myocarditis among patients with cancer.

An expert from Duke Health says that patients with NPM1-mutatant relapsed/refractory acute myeloid leukemia did not experience any significant safety signals following treatment with ziftomenib.

Camrelizumab plus apatinib demonstrates impressive anti-tumor activity in a pretreated population with recurrent or metastatic nasopharyngeal carcinoma, although further research is needed, according to an expert from Memorial Sloan Kettering Cancer Center.

The safety profile of fam-trastuzumab deruxtecan-nxki for managing HER2-expressing tumors in the DESTINY-PanTumor02 trial appears consistent with previously reported findings on the agent.

Patients with advanced clear cell renal cell carcinoma are “unlikely” to experience a clinically meaningful decrease in overall survival following planned treatment cessation with a tyrosine kinase inhibitor.